Metrics as of 10/14/2026, 08:36 AM (Berlin time), refresh in progress.
Artivion Stock
Artivion, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- James Patrick Mackin
- Employees
- 1,800
- Market cap
- $1 B
- IPO
- 12/02/1993
- Web
- artivion.com
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications.…
Artivion stock: price history
1D
-2.0%
1W
-2.2%
1M
-14.8%
6M
-43.7%
YTD
-53.2%
1Y
-47.4%
2Y
-17.6%
5Y
-1.9%
10Y
+27.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~67% stronger price swings than usual
Ask the agents about Artivion
Analyst assessment of Artivion
PRICE TARGET LOW
US$40.00
CONSENSUS
US$42.50
MEDIAN
US$42.50
PRICE TARGET HIGH
US$45.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 18/08/2026
Artivion stock metrics
P/E
-358.39
P/B
2.33
EV/EBITDA
26.78
RETURN ON EQUITY
-3.0%
NET MARGIN
-10.7%
DEBT/EQUITY
0.92
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
94.9%
FLOAT SHARES
46,065,358
AVG. DAILY VOLUME (30D)
597,925
Insider transactions (SEC)
GREEN ANDREW M
GREEN ANDREW M
GREEN ANDREW M
Mackin James P
GREEN ANDREW M
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about Artivion stock
What does Artivion do?
Artivion, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is James Patrick Mackin, the company employs around 1,800 people.
The IPO was on 12/02/1993; the stock trades on NYSE under the ticker AORT.
What do analysts say about Artivion stock?
12 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
The average price target is US$42.50, ranging from US$40.00 to US$45.00, with a median of US$42.50.
This is an external assessment, not a statement by Market Jury.
When does Artivion report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 67% stronger than usual.
Does Artivion pay a dividend?
Yes. The last dividend was US$0.03 per share, ex-date 09/12/2015, paid on 18/12/2015.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to Artivion?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get Artivion stock analyzed?
Clicking "Analyze stock" lets five strategies assess Artivion against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.